Pharmacology/Pharmaceutical Industry | Page 34 of 172 | Links Medicus Content Curation & Alerts in Medicine

RCT: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure.

9 Mar, 2022 | 10:04h | UTC

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine

WHO says COVID boosters needed, reversing previous call.

9 Mar, 2022 | 09:49h | UTC

WHO says COVID boosters needed, reversing previous call – Associated Press

Commentary on Twitter

Who needs a booster? The @WHO reverses its position and supports "urgent and broad" 3-shot vaccination https://t.co/y5pyY9bJr7 @AP The evidence has supported that move for several months.
"Fully vaccinated" = 3-shots
(or confirmed infection-acquired immunity + 1 shot)

— Eric Topol (@EricTopol) March 8, 2022

RCT: Combination treatment with Varenicline and Nicotine patch may increase smoking cessation rates among smokers who drink heavily.

9 Mar, 2022 | 08:44h | UTC

Effect of Combination Treatment With Varenicline and Nicotine Patch on Smoking Cessation Among Smokers Who Drink Heavily: A Randomized Clinical Trial – JAMA Network Open

Commentary: Combination treatment is effective for treating smokers who drink heavily – University of Chicago Medical Center

Commentary on Twitter

In this RCT, the combination of varenicline + nicotine patch was superior to placebo + nicotine patch in increasing smoking quit rates in smokers who drink heavily. https://t.co/UbekBdEjyA

— JAMA Network Open (@JAMANetworkOpen) March 4, 2022

Review: Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.

9 Mar, 2022 | 08:35h | UTC

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies – European Heart Journal

Bisphosphonate nephropathy: A case series and review of the literature.

9 Mar, 2022 | 08:32h | UTC

Bisphosphonate nephropathy: A case series and review of the literature – British Journal of Clinical Pharmacology

RCT: Efficacy of HD201 vs. referent Trastuzumab in patients With ERBB2-positive breast cancer treated in the neoadjuvant setting.

9 Mar, 2022 | 08:22h | UTC

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant SettingA Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology

Commentary on Twitter

https://twitter.com/JAMAOnc/status/1499791783735271426

RCT: Azithromycin is not effective for the prevention of recurrent wheeze following severe respiratory syncytial virus bronchiolitis.

8 Mar, 2022 | 08:49h | UTC

Azithromycin to Prevent Recurrent Wheeze Following Severe Respiratory Syncytial Virus Bronchiolitis – NEJM Evidence

Commentaries:

Study finds azithromycin use during RSV not useful in preventing recurrent wheezing, may cause harm – Vanderbilt University Medical Center

Antibiotic doesn’t prevent future wheezing in babies hospitalized with RSV – Washington University in St. Louis

Commentary on Twitter

This RCT tested oral azithromycin vs placebo to reduce recurrent wheeze (RW) in 1-18-month-olds hospitalized with acute severe RSV bronchiolitis. Azithromycin did not reduce occurrence of RW and may increase risk of RW in some groups. #AAAAI22 #Asthma #EBM https://t.co/jYcBuiQ8aY pic.twitter.com/u65NbQaIlX

— NEJM Evidence (@NEJMEvidence) February 28, 2022

AHA Scientific Statement: Cardio-oncology drug interactions.

8 Mar, 2022 | 09:53h | UTC

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association – Circulation

[News release – not published yet] New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials.

8 Mar, 2022 | 08:53h | UTC

Commentary: New vaccine demonstrates strong protection against severe Covid-19 in clinical trials – CNN

News Release: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Guidelines on management of persons with multimorbidity and polypharmacy.

8 Mar, 2022 | 08:41h | UTC

Italian guidelines on management of persons with multimorbidity and polypharmacy – Aging Clinical and Experimental Research

Guideline for perioperative management of patients with inflammatory rheumatic diseases.

8 Mar, 2022 | 08:43h | UTC

Perioperative management of patients with inflammatory rheumatic diseases – Zeitschrift für Rheumatologie

Study suggests switching among different generic levothyroxine products is not associated with clinically significant changes in TSH level.

8 Mar, 2022 | 08:30h | UTC

Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults – JAMA Internal Medicine (link to abstract – $ for full-text)

Commentary: Generic Levothyroxine Switching and Thyrotropin Levels – American College of Cardiology

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review.

8 Mar, 2022 | 08:16h | UTC

Process evaluation of implementation strategies to reduce potentially inappropriate medication prescribing in older population: A scoping review – Research in Social and Administrative Pharmacy

Commentary on Twitter

A scoping review of implementation strategies to reduce #PIMs in older adults finds multifaceted interventions were the most studied implementation strategies and knowledge gaps exist around sustainability and implementation costs #deprescribing https://t.co/vfUtizxmrn

— deprescribing.org (@deprescribing) March 3, 2022

Review: Innovating medication reviews through a technology-enabled process.

8 Mar, 2022 | 08:13h | UTC

Innovating medication reviews through a technology-enabled process – Research in Social and Administrative Pharmacy

Systematic Review: Anticoagulants for people hospitalized with COVID‐19.

7 Mar, 2022 | 00:48h | UTC

Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library

Summary: Do blood thinners prevent people who are hospitalised with COVID-19 from developing blood clots? – Cochrane Library

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

7 Mar, 2022 | 00:32h | UTC

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial – Clinical Infectious Diseases

Lab study tested an extensive range of possibly effective drug combinations in breast, colon, and pancreatic cancer cells.

7 Mar, 2022 | 00:03h | UTC

Effective drug combinations in breast, colon and pancreatic cancer cells – Nature

Commentaries:

New drug combinations found for resistant cancers – Wellcome Trust Sanger Institute

Study predicts treatment combinations for resistant cancers – Frontline Genomics

Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials.

6 Mar, 2022 | 23:32h | UTC

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials – Journal of Clinical Oncology

Commentaries:

Women at higher risk of severe adverse events from cancer therapy – eCancer

Women Face Higher Risk for Severe AEs From Cancer Therapy – HealthDay

Commentary on Twitter

👀 Women had worse toxicity from #chemotherapy, #immunotherapy or #TargetedTherapy as compared to men in analysis of multiple @SWOG #clinicaltrials 👉 https://t.co/PjmnyJROb4 #leusm #CRCSM #LCSM @DrJoeUnger @DrDawnHershman pic.twitter.com/BJPZQoaI6g

— Journal of Clinical Oncology (@JCO_ASCO) February 23, 2022

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

4 Mar, 2022 | 10:09h | UTC

News Release: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Original study: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Commentaries:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

Commentary from the author on Twitter (thread – click for more)

RECOVERY pre-print: Baricitinib

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis https://t.co/g0cNjaBzEL

— Martin Landray (@MartinLandray) March 3, 2022

Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.

4 Mar, 2022 | 09:57h | UTC

BMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

WHO News Release: WHO updates its treatment guidelines to include molnupiravir

See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ

Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

M-A: Efficacy of covid-19 vaccines in immunocompromised patients.

4 Mar, 2022 | 10:01h | UTC

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

News Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Commentary on Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022